Cholera deaths during outbreaks in Uvira, Eastern Democratic Republic of Congo, September 2021-January 2023

Patrick Musole Bugeme[1,2], Hanmeng Xu[1], Chloe Hutchins[3], Juan Dent Hulse[1], Jaime Mufitini Saidi[4], Baron Bashige Rumedeka[1,4], Moïse Itongwa[1], Justin Bengehya[5], Amanda K Debes[6], Iza Ciglenecki[7], Esperance Tshiwedi[8], Faida Kitoga[8], Tavia Bodisa-Matamu[8], Taty Nadège[9], Hugo Kavunga-Membo[8,10], Jackie Knee[3], Placide Okitayemba Welo[9], Daniel Mukadi-Bamuleka[8,10], Andrew S. Azman[1,11,12*], Espoir Bwenge Malembaka[1,2]

[1]*Department of Epidemiology, Johns Hopkins University, Baltimore, MD 21205, USA*
[2]*Centre for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo*
[3]*Department of Disease Control, London School of Hygiene & Tropical Medicine, UK*
[4]*Ministère de la Santé Publique, Division Provinciale de la Santé Publique du Sud-Kivu, Zone de Santé d'Uvira, Democratic Republic of the Congo*
[4]*Ministère de la Santé Publique, Zone de Santé d'Uvira, Democratic Republic of Congo*
[5]*Ministère de la Santé Publique, Division Provinciale de la Santé Publique du Sud-Kivu, Democratic Republic of the Congo*
[6]*Department of International Health, Johns Hopkins University, Baltimore, MD 21205, USA*
[7]*Médecins Sans Frontières, 1202 Geneva, Switzerland*
[8]*Rodolphe Merieux INRB-Goma Laboratory, Goma, North-Kivu, Democratic Republic of the Congo*
[9]*Programme National d'Elimination de Choléra et lutte contre les autres Maladies 19 Diarrhéiques (PNECHOL-MD), Kinshasa, Democratic Republic of the Congo*
[10]*Institut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the Congo*
[11]*Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals (HUG),, Geneva, Switzerland*
[12]*Division of Tropical and Humanitarian Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland*

*Corresponding author:

Andrew S. Azman (azman@jhu.edu)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA

Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals (HUG),, Geneva, Switzerland

Division of Tropical and Humanitarian Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland

Abstract

Our understanding of the burden and drivers of cholera mortality is hampered by limited surveillance and confirmation capacity. Leveraging enhanced clinical and laboratory surveillance in the cholera-endemic community of Uvira, eastern Democratic Republic of Congo, we describe cholera deaths across two seasonal outbreaks between September 2021-January 2023, following mass vaccination.

Keywords: cholera mortality, confirmation, Democratic Republic of the Congo

Background

Cholera is an acute diarrheal disease that can rapidly cause severe dehydration and death without prompt and aggressive rehydration (*1*). Estimates of the true burden of cholera are highly uncertain due to poor surveillance systems lacking routine identification and testing of suspected cases, and limited documentation of community cases and deaths. In resource-constrained settings, passive, facility-based surveillance data on mortality are likely to be an underestimate of true mortality; contributing factors include limited patient access to health facilities, incentives for under-reporting, and access to confirmatory laboratories for cases and deaths (*2–5*). In the city of Uvira in South Kivu [eastern Democratic Republic of the Congo (DRC)], we implemented an enhanced cholera surveillance system as part of a mass cholera vaccination impact study. Here, we describe cholera deaths across two seasonal outbreaks up to three years after vaccination in Uvira (Figure).

The study

Between September 1, 2021, and January 31, 2023, suspected cholera cases were recruited at the two cholera treatment facilities in Uvira: the Cholera Treatment Centre at the Uvira General Referral Hospital; and Cholera Treatment Unit at the Kalundu CEPAC health center (both designated as CTC herein). A suspected cholera case was any person ≥ 12 months old, reporting ≥ 3 acute, watery, and non-bloody diarrheal stools within 24h before hospitalization. Data on sociodemographic characteristics, clinical manifestations and outcome, and vaccination status were collected using a structured electronic questionnaire. Written consent was obtained from participants. Rectal swabs and stool samples were collected from consenting patients. Rectal swabs were enriched for 6-18 hours in alkaline peptone water at ambient temperature (~30C). Crystal VC Rapid Diagnostic Tests (RDTs;

Arkay, India) were used to test raw stool samples and rectal swab enrichments. Samples

collected after September 2022 were cultured at the CTC laboratory, whereas those collected

before were tested at Rodolphe Mérieux INRB-Goma laboratory in North Kivu. In addition,

stool samples from the 2021-2022 outbreak were spotted onto Whatman 903 Protein Saver

Cards (Cytiva, UK) and tested by PCR at Johns Hopkins University using methods

previously described (*6*).

Community deaths were not systematically captured by the surveillance system, so the study

team learned of suspected community cholera deaths through informal means (Appendix).

Visits were organized to collect additional information on the circumstances of death, socio-

demographics, clinical manifestations, and vaccination status for each suspected community

cholera death. Cholera was the suspected cause of death if the deceased was $\geq$ 12 months old

and their family members reported that they experienced acute watery diarrhea in the 24

hours preceding the death, with no other cause of death reported. No biological samples were

collected from those dying in the community.

Figure. Weekly cholera incidence (top) and death (bottom) by culture confirmation results in Uvira, September 2021 to January 2023. Before September 10, 2022, culture was performed with a significant lag at an external reference laboratory from wet filter papers (INRB Goma), likely leading to reduced sensitivity for *V. cholerae* O1. From September 10, 2022, culture has been performed on-site in Uvira and we expect higher sensitivity. For this reason, we show enriched rapid test positive results as dots to help understand which deaths have more laboratory data supporting *V. cholerae* O1 as the causative agent. Rapid diagnostic tests (a mix of O1 and O1/O139 tests) were also used throughout the study. Community deaths are highlighted with black boxes.

1,237 suspected cholera cases were admitted to the CTCs, of which 777 (65.6%) cases were confirmed by culture or PCR. In the same period, 18 suspected cholera deaths were reported, of which 15 (83%) occurred within CTCs, with a facility-based suspected case fatality ratio (CFR) of: 1.2% (15/1237). Twelve (86%) of the 14 health facility deaths in which a sample was collected tested positive for cholera by RDT, and nine (64.3%) by culture or PCR. The overall culture/PCR-confirmed facility-based CFR was 9/777 (1.2%), though this was significantly higher [8.3% (5/60), p=0.0003] in participants aged ≥ 60 years old [7.1% (8/112)]. The suspected cholera CFR in this age-group was 7.1% (8/112).

Comparison between health facilities deaths and survivors revealed that those dying from cholera tended to be older [median (interquartile range, IQR) age: 62 (27 –74) years] than survivors [median (IQR): 18 (7–34) years], with no difference by sex (Table). Cases who died were twice as likely to have been admitted with severe dehydration compared to

survivors (93.3% vs 45.7%, p<0.001). While cases who died appeared to present for care

later than those who survived, this was not statistically significant. Nine (60%) health facility

deaths occurred after at least one day of hospitalization. Two of the facility deaths, both

culture-positive, were reported to have received one dose of oral cholera vaccine during the

2020 vaccination campaign, but vaccination cards were not available.

Table. Characteristics of patients with cholera who died and survived in the cholera

treatment facilities, Uvira, September 2021 to January 2023

Characteristic	Overall, N = 1,237	Cholera deaths, N = 15	Cholera cases (Survivors), N = 1,222	p-value
Age (continuous)				<0.001
Mean (SD)	23.4 (20.2)	50.4 (27.8)	23.1 (19.8)	
Median (IQR)	18.0 (7.0, 35.0)	62.0 (27.0, 74.0)	18.0 (7.0, 34.0)	
Age group				<0.001
< 5 years	215 (17.4%)	1 (6.7%)	214 (17.5%)	
5-14 years	316 (25.5%)	0 (0.0%)	316 (25.9%)	
15-59 years	594 (48.0%)	6 (40.0%)	588 (48.1%)	
≥ 60 years	112 (9.1%)	8 (53.3%)	104 (8.5%)	
Sex				0.702
Female	599 (48.4%)	8 (53.3%)	591 (48.4%)	
Male	638 (51.6%)	7 (46.7%)	631 (51.6%)	
Level of dehydration on admission				<0.001
Mild to moderate	664 (53.7%)	1 (6.7%)	663 (54.3%)	
Severe	573 (46.3%)	14 (93.3%)	559 (45.7%)	
Time from symptoms onset to hospitalization				0.215
Zero day	688 (55.8%)	7 (46.7%)	681 (55.9%)	
1 day	422 (34.2%)	8 (53.3%)	414 (34.0%)	
≥ 2 days	124 (10.0%)	0 (0.0%)	124 (10.2%)	
Missing	3	0	3	
Duration of hospitalization				<0.001
Zero day	79 (6.4%)	6 (40.0%)	73 (6.0%)	
1 day	318 (25.7%)	4 (26.7%)	314 (25.7%)	
≥ 2 days	839 (67.9%)	5 (33.3%)	834 (68.3%)	
Missing	1	0	1	
Comorbidities (diabetes, high blood pressure and/or HIV)				0.385

No	587 (93.3%)	6 (85.7%)	581 (93.4%)	
Yes	42 (6.7%)	1 (14.3%)	41 (6.6%)	
Missing	608	8	600	
Sought care at another health facility				>0.999
No	1,075 (86.9%)	13 (86.7%)	1,062 (86.9%)	
Yes	162 (13.1%)	2 (13.3%)	160 (13.1%)	
Treated at home or pharmacy				0.593
No	575 (46.5%)	8 (53.3%)	567 (46.4%)	
Yes	662 (53.5%)	7 (46.7%)	655 (53.6%)	
Use of antibiotics before admission				0.328
No	670 (54.2%)	10 (66.7%)	660 (54.0%)	
Yes	567 (45.8%)	5 (33.3%)	562 (46.0%)	
APW-enriched RDT				0.049
Negative	459 (39.9%)	2 (14.3%)	457 (40.3%)	
Positive	690 (60.1%)	12 (85.7%)	678 (59.7%)	
Missing	88	1	87	
Confirmed cholera by culture/PCR				>0.999
Negative	407 (34.4%)	5 (35.7%)	402 (34.4%)	
Positive	777 (65.6%)	9 (64.3%)	768 (65.6%)	
Missing	53	1	52	
Vaccination status				0.744*
Not vaccinated	930 (77.1%)	11 (84.6%)	919 (77.0%)	
At least 1 dose	276 (22.9%)	2 (15.4%)	274 (23.0%)	
Missing	31	2	29	

Data are n (proportion). P values are derived from Pearson's Chi-squared test or Fisher's exact test comparing attributes
between survivors and those who died, denoted by *. A confirmed cholera case was defined by a positive PCR or culture
result. A negative case was confirmed by simultaneous negative PCR and culture, or by a negative culture result when PCR
was not done.

The community deaths were in the 5–10-year (n=1) and 60–69-year (n=2) age groups, with

one female. Deaths are briefly described in the Appendix.

The 1.2% facility-based CFR observed from this passive surveillance system was slightly

higher than the WHO target of <1%, aligning with that reported between 2008-2017 in DRC

hotspot health zones (1.1%) (7). While we captured some community deaths, the true cholera

mortality burden in Uvira is likely higher than reported here due to lack of a robust

community-based surveillance and the important number of private health facilities that are

not integrated into the official surveillance system. The limited existing studies comparing

the reported number of facility deaths to those occurring in both facilities and the community

suggest this gap is large (*2–4,8*). A study from rural Kenya showed that while suspected

cholera cases were under-reported by 37%, suspected cholera deaths were under-reported by

200%, implying a 52% underestimate of the community CFR (*2*). In Cameroon, 44% of

suspected cholera deaths occurred in the community or during transit to a treatment unit (*3*).

During the 2010-2011 cholera outbreak in Haiti, community surveys led to almost a 3-fold

higher death toll in certain areas compared to official facility-based estimates (*4*).

A previous report from across DRC suggested that 20.8% of the suspected cholera deaths

during the 2008-2017 period were among those under five years old, a stark contrast to the

6.6% in our study (*7*). This difference may be a result of several factors including the

systematic application of case definitions in Uvira (i.e., improved specificity), differences in

health seeking behaviors and/or in the quality of care given to young patients in Uvira.

Over half (53.3%) of facility deaths occurred among patients >60 years, leading to an

unacceptably high age group-specific CFR (8.3%). Moreover, 60% of deaths happened after

≥ 1 day of hospitalization. This may be because clinical assessment and management of

severe dehydration is challenging in the elderly who might have many other associated

comorbidities that might require slower rehydration pace to avoid fluid overload.

Complications related to underlying comorbidities like cardiovascular diseases, diabetes

mellitus, anemia, or malnutrition may be overlooked in cholera treatment centers, particularly

in the middle of an outbreak, as rehydration is the priority. CTCs in most humanitarian

settings, including in our study site, are not sufficiently equipped for an adequate assessment

and management of associated diseases, including chronic morbidities. Ensuring that CTCs

offer comprehensive and person-centered care (as opposed to solely dehydration-centered

care) might contribute to the reduction of cholera CFR.

167 Conclusions

While the public health community strives to improve the cholera surveillance (*9*), describing

the magnitude and drivers of community and confirmed facility deaths is critical to help

correctly target those most at risk, and improve patient care and estimates of cholera burden.

This study provides a unique insight into the true confirmed cholera mortality in a resource-

constrained and endemic setting. Studies with larger sample sizes and in different endemicity

settings are needed to confirm our findings.

About the Author

Patrick Musole Bugeme is a medical doctor working in the Infectious Disease Dynamics

group at the Johns Hopkins Bloomberg School of Public Health and based in Uvira in the

Democratic Republic of Congo (DRC) where he coordinates the study site activities for an

impact evaluation of mass oral cholera vaccination campaigns. Patrick also works as a part-

time volunteer physician in the department of pediatrics at the Uvira General Referral

Hospital and has an affiliation as researcher in the Center for Tropical Diseases and Global

Health at the Université Catholique de Bukavu in DRC. His research interests include vaccine

preventable diseases, vaccine hesitancy, healthcare seeking behavior and global health

Acknowledgments
184
185   This work was supported by the Wellcome Trust and Gavi (GAVI-RFP-2019-062).
186

References

1. Kanungo S, Azman AS, Ramamurthy T, Deen J, Dutta S. Cholera. Lancet. 2022 Apr 9;399(10333):1429–40.

2. Shikanga OT, Mutonga D, Abade M, Amwayi S, Ope M, Limo H, et al. High mortality in a cholera outbreak in western Kenya after post-election violence in 2008. Am J Trop Med Hyg. 2009 Dec;81(6):1085–90.

3. Djouma FN, Ateudjieu J, Ram M, Debes AK, Sack DA. Factors Associated with Fatal Outcomes Following Cholera-Like Syndrome in Far North Region of Cameroon: A Community-Based Survey. Am J Trop Med Hyg. 2016 Dec 7;95(6):1287–91.

4. Luquero FJ, Rondy M, Boncy J, Munger A, Mekaoui H, Rymshaw E, et al. Mortality Rates during Cholera Epidemic, Haiti, 2010-2011. Emerg Infect Dis. 2016 Mar;22(3):410–6.

5. Azman AS, Moore SM, Lessler J. Surveillance and the global fight against cholera: Setting priorities and tracking progress. Vaccine. 2020 Feb 29;38 Suppl 1(Suppl 1):A28–30.

6. Debes AK, Ateudjieu J, Guenou E, Ebile W, Sonkoua IT, Njimbia AC, et al. Clinical and Environmental Surveillance for Vibrio cholerae in Resource Constrained Areas: Application During a 1-Year Surveillance in the Far North Region of Cameroon. Am J Trop Med Hyg. 2016 Mar;94(3):537–43.

7. Ingelbeen B, Hendrickx D, Miwanda B, van der Sande MAB, Mossoko M, Vochten H, et al. Recurrent Cholera Outbreaks, Democratic Republic of the Congo, 2008-2017. Emerg Infect Dis. 2019 May;25(5):856–64.

8. Pampaka D, Ciglenecki Z, Alberti K, Olson D. Risk factors of cholera mortality: a scoping review [Internet]. Global Task Force on Cholera Control (GTFCC) ; 2022 Feb [cited 2023 Mar 14]. Available from: https://www.gtfcc.org/wp-content/uploads/2023/02/gtfcc-risk-factors-of-cholera-mortality.pdf

9. GTFCC. Public health surveillance for cholera: Interim guidance [Internet]. Global Taskforce on Cholera Control (GTFCC); 2023 Feb [cited 2023 Mar 14]. Available from: https://www.gtfcc.org/wp-content/uploads/2023/02/gtfcc-public-health-surveillance-for-cholera-interim-guidance.pdf